Meningitis

Trial Shows Promising Results in Vaccine Development

Published in Vaccine Weekly, February 17th, 1997

North American Vaccine, Beltsville, Maryland, announced that it has completed a Phase I clinical trial for the company's polysaccharide conjugate vaccine against Group C meningococcal infection.

The safety and immunogenicity clinical trial was sponsored by North American Vaccine and was conducted in conjunction with the Institute of Child Health at the University College London Medical School, London, United Kingdom. The results from the adult clinical study revealed that the meningococcal C polysaccharide conjugate vaccine was well-tolerated with minimal reactogenicity and no serious side-effects. Additionally, antibodies elicited by immunization with the conjugate...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1997-02-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry